Erlanson DA - Search Results

1

Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry.

Cancilla MT, He MM, Viswanathan N, Simmons RL, Taylor M, Fung AD, Cao K, Erlanson DA. Cancilla MT, et al. Among authors: erlanson da. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3978-81. doi: 10.1016/j.bmcl.2008.06.011. Epub 2008 Jun 10. Bioorg Med Chem Lett. 2008. PMID: 18579375

2

Site-directed ligand discovery.

Erlanson DA, Braisted AC, Raphael DR, Randal M, Stroud RM, Gordon EM, Wells JA. Erlanson DA, et al. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9367-72. doi: 10.1073/pnas.97.17.9367. Proc Natl Acad Sci U S A. 2000. PMID: 10944209 Free PMC article.

3

Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design.

Choong IC, Lew W, Lee D, Pham P, Burdett MT, Lam JW, Wiesmann C, Luong TN, Fahr B, DeLano WL, McDowell RS, Allen DA, Erlanson DA, Gordon EM, O'Brien T. Choong IC, et al. Among authors: erlanson da. J Med Chem. 2002 Nov 7;45(23):5005-22. doi: 10.1021/jm020230j. J Med Chem. 2002. PMID: 12408711

4

In situ assembly of enzyme inhibitors using extended tethering.

Erlanson DA, Lam JW, Wiesmann C, Luong TN, Simmons RL, DeLano WL, Choong IC, Burdett MT, Flanagan WM, Lee D, Gordon EM, O'Brien T. Erlanson DA, et al. Nat Biotechnol. 2003 Mar;21(3):308-14. doi: 10.1038/nbt786. Epub 2003 Feb 3. Nat Biotechnol. 2003. PMID: 12563278

5

Discovery of a new phosphotyrosine mimetic for PTP1B using breakaway tethering.

Erlanson DA, McDowell RS, He MM, Randal M, Simmons RL, Kung J, Waight A, Hansen SK. Erlanson DA, et al. J Am Chem Soc. 2003 May 14;125(19):5602-3. doi: 10.1021/ja034440c. J Am Chem Soc. 2003. PMID: 12733877

6

Tethering: fragment-based drug discovery.

Erlanson DA, Wells JA, Braisted AC. Erlanson DA, et al. Annu Rev Biophys Biomol Struct. 2004;33:199-223. doi: 10.1146/annurev.biophys.33.110502.140409. Annu Rev Biophys Biomol Struct. 2004. PMID: 15139811 Review.

7

Fragment-based drug discovery.

Erlanson DA, McDowell RS, O'Brien T. Erlanson DA, et al. J Med Chem. 2004 Jul 1;47(14):3463-82. doi: 10.1021/jm040031v. J Med Chem. 2004. PMID: 15214773 Review. No abstract available.

8

Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly.

Erlanson DA, Hansen SK. Erlanson DA, et al. Curr Opin Chem Biol. 2004 Aug;8(4):399-406. doi: 10.1016/j.cbpa.2004.06.010. Curr Opin Chem Biol. 2004. PMID: 15288250 Review.

9

Allosteric inhibition of PTP1B activity by selective modification of a non-active site cysteine residue.

Hansen SK, Cancilla MT, Shiau TP, Kung J, Chen T, Erlanson DA. Hansen SK, et al. Among authors: erlanson da. Biochemistry. 2005 May 31;44(21):7704-12. doi: 10.1021/bi047417s. Biochemistry. 2005. PMID: 15909985

10

Fragment-based lead discovery: a chemical update.

Erlanson DA. Erlanson DA. Curr Opin Biotechnol. 2006 Dec;17(6):643-52. doi: 10.1016/j.copbio.2006.10.007. Epub 2006 Nov 3. Curr Opin Biotechnol. 2006. PMID: 17084612 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

46 results

Search Page

Filters